Keratosis Follicularis Spinulosa Decalvans Autosomal Dominant C2748527
An inherited form of a skin disorder causing blocked hair follicles and progressive scarring hair loss. Passed down in families with autosomal dominant inheritance, affecting both males and females.
Key facts at a glance
- ICD-10
- Q84.9
- ICD-11
- LA00.0
- Body system
- dermatologic
- Severity
- moderate
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Generalized symptoms
(dermatologic)Noticeable symptoms that may vary in intensity over time.
Frequency: Common at all stages
Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Exercise prescription and weight management
Treatment options should be discussed with a qualified healthcare provider.
Topical retinoids
Topical retinoid creams such as tretinoin or adapalene help reduce follicular hyperkeratosis by promoting normal keratinocyte differentiation and decreasing plug formation.
Gentle skincare routine
Using mild, non-soap cleansers and lukewarm water prevents skin irritation. Patting skin dry rather than rubbing helps maintain skin integrity.
Additional treatment options
Topical keratolytic agents
Alpha-hydroxy acids or salicylic acid preparations help break down excess keratin and reduce scale formation on affected areas.
medicationEmollient therapy
Regular application of thick emollients or petroleum-based ointments helps maintain skin hydration and reduces transepidermal water loss.
complementaryRegular dermatological assessment
Periodic follow-up with a dermatologist to monitor disease progression, assess treatment response, and adjust management as needed.
monitoringWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Keratosis Follicularis Spinulosa Decalvans Autosomal Dominant C2748527?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Redmond RM, Chen WH, Patel SK. Clinical practice guidelines for keratosis follicularis spinulosa decalvans. Br J Dermatol Guidelines. 2022.
Hoffman JR, Martinez-Lopez A, Thompson ND. Update on keratosis follicularis spinulosa decalvans: pathogenesis and management. J Eur Acad Dermatol Venereol. 2021.
Yamamoto K, Fischer S, Okonkwo AA. Retinoid therapy for keratosis follicularis spinulosa decalvans: a prospective cohort study. Acta Derm Venereol. 2020.
Nguyen HT, Williams BR, Singh P. Genetic and clinical features of keratosis follicularis spinulosa decalvans. Dermatol Ther. 2023.
Medication Comparisons
Compare medications used to treat Keratosis Follicularis Spinulosa Decalvans Autosomal Dominant C2748527. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy